Barrett食管生物标志物在风险分层方面的研究现状和挑战  

Current Status and Challenges of Research on Biomarkers of Barrett’s Esophagus in Risk Stratification

作　　者：王晓 李黎[3,4] 何云云 方勇[1,2] 张嘉俐 张笑 熊光苏 WANG Xiao;LI Li;HE Yunyun;FANG Yong;ZHANG Jiali;ZHANG Xiao;XIONG Guangsu(Department of Gastroenterology,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200437;Shanghai University of Traditional Chinese Medicine,Shanghai;Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai;Institute of Arthritis Research in Integrative Medicine,Shanghai Academy of Traditional Chinese Medicine,Shanghai)

机构地区：[1]上海中医药大学附属岳阳中西医结合医院消化内科,200437 [2]上海中医药大学 [3]上海中医药大学附属光华医院 [4]上海市中医药研究院中西医结合关节炎研究所

出　　处：《胃肠病学》2022年第7期444-448,共5页Chinese Journal of Gastroenterology

基　　金：上海市卫生健康委员会科研课题(201940364)。

摘　　要：Barrett食管(BE)被公认为食管腺癌(EAC)的癌前病变和最强风险因素,其漏诊率高,恶变为EAC后生存率低,且当前监测方法和治疗手段等均较为有限。因此,筛查BE的生物标志物被寄予厚望,尤其是BE恶变进展风险分层生物标志物有助于早期、快速、准确判断疾病进程,指导BE患者分层管理和精准治疗,降低恶变率和死亡率。本文以肿瘤内异质性的动态进化过程为主线,从遗传学、表观遗传学和血清学角度切入,综述BE生物标志物在风险分层方面的研究现状和挑战。Barrett’s esophagus(BE)is the recognized precancerous lesion and risk factor for esophageal adenocarcinoma(EAC),and has a high miss diagnosis rate and low survival rate when malignantly transformed into EAC,moreover,there are only limited monitoring method and treatment.Therefore,the screening of biomarkers is highly expected,especially the risk stratification biomarkers related to the progression of malignant transformation of BE.Such biomarkers can help to determine early,quickly and accurately the disease process,and guide the stratified management and precise treatment of BE,reduce the malignancy rate and mortality.This article focused on the dynamic evolutionary process of intra‑tumor heterogeneity,and reviewed the current status and challenges of research on BE biomarkers in risk stratification from the genetics,epigenetics and serology perspectives.

关 键 词：BARRETT食管 生物标志物 风险分层 分级管理 精准治疗 

分 类 号：R735.1[医药卫生—肿瘤]